High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML by Concomitant Analysis of Cell Surface antigens, Signaling Pathways and Anti-apoptotic Proteins
These symptoms could mask disease flares, complicate assessment of treatment response to IBD-specific therapies, or reduce quality of life in patients already burdened by gastrointestinal symptoms
Navigator Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM
HendersonSTVogelJLBarrLJGarvinFJonesJJCostantiniLC.Study of the ketogenic agent Ac-1202 in mild to moderate Alzheimers disease: A randomized, double-blind, placebo-controlled, multicenter trial
Dalton, T
As our bodies age, and depending on our environmental conditions, our natural abilities to produce many compounds like glutathione can slow down and become weaker
